⌘K
Loading ticker…
As of 2026-08-24, Akebia Therapeutics, Inc. (AKBA) has a 3-month relative strength percentile of 28 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 38. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 6.4%, relative volume 1.51×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
AKBA is in a stage 4 downtrend, week 3. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -21.1% / -32.5%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
AKBA is held by 15 ETFs as of May 2026. Top owner: VTWO at 0.01% weight, $1M notional. Top 3 carry $3M.
Held by 36 ETFs · $46M across latest filings · largest weight 0.32% (QQQS).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.01% | $1M | — |
| SCHASchwab U.S. Small-Cap ETF | 0.01% | $1M | — |
| VHTVanguard Health Care ETF | 0.00% | $767K | — |
| GSSC | 0.03% | $333K | −0.02 pp |
| SBIO | 0.17% | $282K | −0.05 pp |
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.01% |
| $187K |
| — |
| QQQS | 0.32% | $60K | −0.07 pp |
| VTWG | 0.00% | $27K | — |
| VTHRVanguard Russell 3000 ETF | 0.00% | $21K | — |
| ITWO | 0.01% | $12K | — |
Showing 10 of 15 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AKBA Jan avg: 12.53% median: 13.54% win: 75% σ: 19.91% n: 4 2022-04-12 → 2026-07-31 | AKBA Feb avg: 0.83% median: -6.52% win: 25% σ: 22.55% n: 4 2022-04-12 → 2026-07-31 | AKBA Mar avg: -1.95% median: 4.95% win: 75% σ: 21.67% n: 4 2022-04-12 → 2026-07-31 | AKBA Apr avg: 7.40% median: -0.72% win: 40% σ: 37.28% n: 5 2022-04-12 → 2026-07-31 | AKBA May avg: -1.58% median: -10.91% win: 40% σ: 21.11% n: 5 2022-04-12 → 2026-07-31 | AKBA Jun avg: 1.28% median: -4.54% win: 40% σ: 13.97% n: 5 2022-04-12 → 2026-07-31 | AKBA Jul avg: 29.11% median: 15.79% win: 100% σ: 32.34% n: 5 2022-04-12 → 2026-07-31 | AKBA Aug avg: -6.52% median: -10.81% win: 25% σ: 13.27% n: 4 2022-04-12 → 2026-07-31 (current) | AKBA Sep avg: -14.77% median: -14.02% win: 0% σ: 2.29% n: 4 2022-04-12 → 2026-07-31 | AKBA Oct avg: -8.90% median: -19.28% win: 25% σ: 23.17% n: 4 2022-04-12 → 2026-07-31 | AKBA Nov avg: 5.58% median: 13.37% win: 75% σ: 23.99% n: 4 2022-04-12 → 2026-07-31 | AKBA Dec avg: 31.11% median: 9.44% win: 75% σ: 55.74% n: 4 2022-04-12 → 2026-07-31 |